- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene
© Presta et al; licensee BioMed Central Ltd. 2005
Received: 14 April 2005
Accepted: 19 July 2005
Published: 19 July 2005
Recovery of iodide uptake in thyroid cancer cells by means of obtaining the functional expression of the sodium/iodide symporter (NIS) represents an innovative strategy for the treatment of poorly differentiated thyroid cancer. However, the NIS gene expression alone is not always sufficient to restore radioiodine concentration ability in these tumour cells.
In this study, the anaplastic thyroid carcinoma ARO cells were stably transfected with a Pax8 gene expression vector. A quantitative RT-PCR was performed to assess the thyroid specific gene expression in selected clones. The presence of NIS protein was detected by Western blot and localized by immunofluorescence. A iodide uptake assay was also performed to verify the functional effect of NIS induction and differentiation switch.
The clones overexpressing Pax8 showed the re-activation of several thyroid specific genes including NIS, Pendrin, Thyroglobulin, TPO and TTF1. In ARO-Pax8 clones NIS protein was also localized both in cell cytoplasm and membrane. Thus, the ability to uptake the radioiodine was partially restored, associated to a high rate of efflux. In addition, ARO cells expressing Pax8 presented a lower rate of cell growth.
These finding demonstrate that induction of Pax8 expression may determine a re-differentiation of thyroid cancer cells, including a partial recovery of iodide uptake, fundamental requisite for a radioiodine-based therapeutic approach for thyroid tumours.
Thyroid tumours show a good long-term survival, but, when we consider the poorly differentiated histotypes and in particular the anaplastic carcinoma, the prognosis is very poor [1, 2]. A major determinant of such an opposite behaviour is the lost ability to concentrate the radioiodine, used as very effective tool for diagnosis and treatment for both tumour remnants or distant metastases . The loss of iodide uptake capacity in poorly differentiated thyroid carcinomas is mainly due to the reduced/lost functional expression of the sodium/iodide symporter (NIS), with a defect occurring mainly at gene expression level, but in some case involving post-transcriptional or other unknown alterations [4–7]. For this reason, many strategies have been used and are currently in progress in order to re-establish iodide uptake function by means of re-expressing the NIS in tumour cells. At present, two different strategies are based on: a. introducing NIS gene in cancer cells through a viral vector; b. stimulating endogenous NIS gene expression [5, 7]. The latter approach may take advantage from the description and characterization of the human NIS gene promoter as well as studies regarding NIS expression regulation [4–7]. Among the physiological stimulators of NIS gene transcription, a pivotal role is played by the thyroid-specific transcription factor Pax8 [8–10]. This homeobox protein is able to regulate, in normal thyroid cells, the expression of many thyroid specific protein and is often reduced in thyroid tumours, especially in the less differentiated histotypes .
In this study we analysed the effects of Pax8 overexpression on a human thyroid anaplastic cancer cell line ARO cells. It is a widely used cell line which resembles the behaviour of poorly differentiated thyroid tumours, including a very low iodide uptake function as well as lost of NIS and Pax8 gene expression, together with several other markers of thyrocyte differentiation . By restoring Pax8 expression, we observed the recovery of NIS expression, together with other markers of thyroid differentiation, associated to partial ability to uptake the radioiodine.
Recombinant plasmid construction
The plasmid vector pCMV and the full length cDNA fragment of Pax8 A (kindly provided by Dr. Di Lauro) , were cleaved by Kpn I and Eco RI. The cleaved products were ligated using T4DNA ligase into pCMV-Script cloning and expression vector (Stratagene, La Jolla, CA, USA). DH5 alpha cells were transformed using the recombinant product pCMV/Pax8 and then screened for the positive clones containing the inserted fragment by colony-PCR techniques. The positive colonies were amplified, extracted, purified and identified by endonuclease cleavage. The sequences of the inserted fragments were confirmed by automated sequencing using ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA).
Cell cultures and stable transfection
ARO cells were cultured in RPMI 1640 medium with 10% foetal bovine serum (Gibco, Milano, Italy) and containing penicillin/streptomycin and amphotericin B (Sigma-Aldrich S.r.l., Milano, Italy). The non-liposomal lipid mixture FUGENE 6 (Roche diagnostics, Monza, Italy) was used for transfection. ARO cells were plated at 3 × 105 cells/60 mm culture dish 24 h prior to transfection. 2 mg of the construct and 2 μg of empty vector in 200 μl of serum free medium and 12 μl of FUGENE 6 mixture each, were used for two different transfections. After 45 min of incubation at room temperature, the transfection mixture was added to the dishes with 2 ml of fresh complete medium. The cells were grown for 24 h before adding 400 μg/ml neomycin (Sigma-Aldrich S.r.l.) for selection and after 3 days the transfected cultures were split for single clone isolation. After propagation, total RNA was extracted from 24 isolated clones for screening of Pax8 gene expression by a quantitative RT-PCR. Cells transfected with the empty vector (ARO-pCMV) were used as control. FRTL-5 and CHO cells, used as additional control, were cultured as described previously .
RNA extraction, reverse transcription and quantitative PCR
Sequences of primer pairs and TaqMan probes
Protein extraction, western blot analysis and immunofluorescence
Total proteins were extracted from thyroid cell lines as described previously . Briefly, confluent cells from 3 Petri dishes were collected and homogenized in 1 ml of buffer containing 250 mM sucrose, 10 mM HEPES-KOH (pH 7.5), 1 mM EDTA, 1 mM PMSF, 10 μg/ml leupeptin, 10 μg/ml aprotinin (Sigma-Aldrich S.r.l.). The homogenate was centrifuged at 14000 × g (4°C for 15 min) and the supernatant (which contained the whole cell lysate) was quantified spectrophotometrically using the Bradford method. Twenty micrograms of proteins were loaded on a 4–20% gradient SDS-polyacrylamide gel and subjected to electrophoresis at a constant voltage (110 V). Electroblotting to a Hybond ECL-PVDF nitrocellulose membrane (Amersham Pharmacia biotech., Milano, Italy) was performed for 2 h at 125 mA using a Mini Trans blot electroblotting system (Bio-rad Laboratories S.r.l, Milano, Italy). Blocking was done using TTBS/milk (TBS, 1% Tween 20, and 5% non fat dry milk) for 2 h at room temperature. The membrane was then incubated with a 1/500 dilution of affinity purified rabbit anti-NIS polyclonal antibody  or a 1/5000 dilution of mouse monoclonal anti-human beta-actin antibody, overnight at 4°C in TTBS/milk. After one 15 min and two 5 min washes in TTBS, the membrane was incubated with a 1/20000 dilution of a horse radish peroxidase conjugated anti-rabbit or anti-mouse antibody (Transduction Laboratories, Lexington, KY, USA) in TTBS/milk. After one 15 min and two 5 min washes in TTBS, the protein was visualized by an enhanced chemiluminescence Western blot detection system (ECL plus, Amersham Pharmacia biotech.).
For immunofluorescence analysis, the cells were plated on glass coverslips and fixed using PBS containing 4% paraformaldehyde for 10 min at RT. Then the fixative was aspirated and the cells washed 3 times for 5 min each with PBS. The cells were incubated with blocking buffer (PBS 1× + BSA 1%) for 15 min at RT. Immunostaining was performed using 1:600 dilution of a rabbit polyclonal antibody anti h-NIS  for 1 h at RT. After three 5-min washes in PBS, the cells were incubated with secondary antibody conjugate with FITC (Sigma Aldrich S.r.l.) diluted 1:160 in PBS 1×, for 30 min at RT, re-washed in PBS and incubated in Hoechst 1× for 3 min at RT. After three final PBS washes, the cells were mounted with Vectashield (Vector Laboratories, Inc. Burlingame, CA, USA).
Iodide uptake, efflux rate and cell growth rate assay
Uptake of 125I was measured as previously described . Briefly, cells were splitted and seeded into 12-well plates and, after aspirating the culture medium, washed with 1 ml of Hank's balanced salt solution (HBSS) (Life technologies S.r.l) supplemented with Hepes 10 mM, pH 7.3. 125I uptake was initiated by adding to each well 500 μl buffered HBSS containing 0.1 μCi carrier-free Na125I and 10 μM NaI to obtain a specific activity of 20 mCi/mmol.
In half of the wells, this assay buffer was supplemented with the NIS inhibitor KClO4 (10 μM) to control for specific uptake. After 40 min at 37°C in a humid atmosphere, the radioactive medium was aspirated and cells were washed with 1 ml of ice-cold HBSS. One ml of 95% ethanol was added to each well for 20 min and then transferred into vials for counting with a gamma counter. Iodide uptake was expressed as picomoles per μg of DNA. Each experiment was done at least twice in quadruplicates and the FRTL-5 cells and CHO cells were used, respectively, as positive and negative controls.
Iodide efflux in wild-type and transfected ARO cells, as well FRTL-5 cells, was evaluated as previously described by Arturi et al. .
For cell growth rate analysis, 105 cells were plated in 60 mm dishes. Seven hours were considered as extra time needed from cells to sediment and start to proliferate. Cells were harvested after 24, 48 and 72 hours and the number of cells was determined by Neubauer cell counting chamber.
Radioiodide uptake in wild-type and transfected ARO cells
Iodide uptake (cpm/well)
133 ± 35
78 ± 26
137 ± 42
82 ± 47
ARO-PAX8 clone 8
307 ± 43
126 ± 27
ARO-PAX8 clone 21
257 ± 36
104 ± 26
4350 ± 320
40 ± 12
A modified gene expression represents the basis for the development and acquisition of the abnormal growth and differentiation characteristics of tumour cells. Since the regulation of the gene expression takes place mainly at transcriptional level, structural or functional alterations of transcription factors, especially those specific for a given tissue, play a key role in the oncogenic process . In thyroid cells, the simultaneous expression of a cohort of tissue-specific transcription factors, including TTF1, TTF2, Pax8 and HEX has been described . Their expression and correct function is essential for the normal development of thyroid gland, and is often altered (reduced or lost) in thyroid tumours, especially in the poorly differentiated histotypes . As a result, thyroid tumour cells present a dedifferentiated phenotype, including a reduced/lost ability to concentrate the radioiodine. This feature represents one of the major determinant of the poor prognosis of less differentiated thyroid carcinomas, since it does not allow the use of radioiodine as diagnostic and therapeutic tool for both tumour remnants or distant metastases. For this reason, attempts to reintroduce such a functional activity in tumour cells have represented the goal of many studies. The cloning and characterization of the protein responsible for iodide uptake, the NIS , has opened the way to novel therapeutic strategies based on induction of iodide uptake ability in tumour cells by recovery the expression of the NIS gene. Subsequently, a NIS-based gene therapy approach by using viral vectors has been exploited [4–7]: despite promising results obtained in both in vitro and in vivo experimental models, unresolved issues still remain before proposing such a treatment on humans, mainly a great efflux rate of the administered radioiodine which makes the effective dose of radioisotope (to be administered to destroy the tumour tissue) too high to be side effect free. A parallel approach to restore radioiodine uptake is to induce endogenous NIS expression and correct function by acting on its transcriptional regulation. Various molecules have been challenged, including retinoids, demethylating agents and inhibitors of histone deacetylation [21–25], with preliminary promising effects in various in vitro and in vivo experimental models. However, in poorly differentiated thyroid tumour cells, re-expression of NIS protein is not always accompanied by recovery of its function  and, at present, despite their unequivocal activity in vitro, retinoids did not show a sufficient effectiveness in clinical trials on human patients . Probably, alterations of other proteins, including some involved in the intrathyroidal metabolism of iodine or in the correct folding, trafficking, polar localization and function of the NIS, do occur in tumour cells, making not fully effective the simple restoration of NIS expression.
In this work, we explored an alternative way to recover radioiodine concentration ability in thyroid tumour cells. Indeed, we tried to activate the transcriptional machinery which physiologically control NIS gene expression by acting on its promoter, as well as other thyroid specific gene cooperating to express the differentiated thyrocyte phenotype. On this regard, the paired domain-containing protein Pax8 has been characterized for its physiological role in the development of thyroid tissue and maintenance of thyrocyte differentiation phenotype [28, 29]. Moreover, reduction/lost of Pax8 expression has been described in thyroid tumour tissues and cell lines [, our unpublished observations]. Pax8-binding sites have been described in the promoters of human TPO, Thyroglobulin and recently, also NIS gene [8, 9]. In addition, re-expression of Pax8 was associated with the recovery of the NIS, as well as TPO and Tg mRNA expression in a rat thyroid cell line . An effect on Tg and TPO promoter activity had been previously described, in cooperation with TTF-1, also in human thyroid tumour cell lines .
Our study demonstrates that thyroid tumour cells expressing Pax8 after stable transfection become able to uptake the radioiodine, even if in absence of a full recovery of NIS protein expression on their plasmamembrane. In addition, other markers of thyroid differentiation were detectable after Pax8 expression, including proteins involved in the intrathyroidal metabolism of iodine such as TPO and pendrin. The expression levels of these thyroid-specific genes were strictly related to the amount of Pax8 expressed in the transfected clones, emphasizing the importance of the levels of this transcription factor for determining a differentiated phenotype . It is of interest also our finding of the recovery of TTF-1 gene expression in the cells with higher levels of Pax8 which suggests a regulatory role for Pax8 at TTF-1 gene promoter level. It may contribute to the phenotypical effects observed and confirms the existence of various levels of cooperation among tissue specific transcription factors . On this regard, few data are available about TTF1 gene promoter, although previous experimental data had suggested the TTF1 gene as a candidate target for regulation by homeobox proteins .
However, Pax8 and TTF1 do not determine a full recovery of normal thyrocyte phenotype, as demonstrated by the presence of lower expression levels of the transcripts in comparison with normal thyroid tissue and the absence of detectable levels of the TSH receptor even in the clones overexpressing Pax8, and, more important, the low intracellular retention of radioiodide. In ARO cells, a greater efflux rate had been also observed after overexpression of exogenous NIS gene inserted in a viral vector ; similarly, only a faint iodide uptake reappeared in BHP18-21v thyroid tumour cells expressing TTF1 . Moreover, contrasting results have been reported after stimulation of endogenous NIS expression by inhibition of histone deacetylation: by using valproic acid, Fortunati et al.  did not obtain a correct localization of the NIS protein in the thyrocyte plasmamembrane, whereas Furuya et al.  described a full recovery of iodide uptake also in ARO cells using the histone deacetylase inhibitor depsipeptide. In addition, our observation of the slower growth rate of ARO-Pax8 cells suggest a role for Pax8 in the control of such a function, until now never detected. Altogether, these data indicate that in addition to act on NIS transcription, a more complex strategy including the correct targeting to the plasmamembrane is required to reach the goal of an effective radioiodine intracellular concentration.
Our finding demonstrate that overexpression of thyroid-specific transcription factors may be a first step to obtain the radioiodine concentration by the transformed thyrocytes, by acting on a pool of differentiation markers including the NIS. Our data, therefore, represent a very promising starting point for further investigations and strategies exploiting this effect of Pax8, eventually in combination of other thyroid-specific transcription factors, for extending radioiodine treatment also to the less differentiated thyroid tumours.
This work was granted by MIUR-Cofin 2003 to D. Russo, by Ministry of Health and MIUR-Cofin 2004 to Prof. S. Filetti. I. Presta was supported by a fellowship from AIRC/FIRC.
- Schlumberger M: Papillary and follicular thyroid carcinoma. N Engl J Med. 1998, 338: 297-306. 10.1056/NEJM199801293380506.View ArticlePubMedGoogle Scholar
- Sherman SI: Thyroid carcinoma. Lancet. 2003, 361: 501-511. 10.1016/S0140-6736(03)12488-9.View ArticlePubMedGoogle Scholar
- Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C: Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986, 63: 960-967.View ArticlePubMedGoogle Scholar
- Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M: Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999, 141: 443-457. 10.1530/eje.0.1410443.View ArticlePubMedGoogle Scholar
- Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC: The Sodium/iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab. 2001, 86: 3327-3335. 10.1210/jc.86.7.3327.View ArticlePubMedGoogle Scholar
- Shen DHJ, Kloos RT, Mazzaferri EL, Jhiang SM: Sodium/iodide symporter in health and disease. Thyroid. 2001, 11: 415-425. 10.1089/105072501300176372.View ArticlePubMedGoogle Scholar
- Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N: The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003, 24: 48-77. 10.1210/er.2001-0029.View ArticlePubMedGoogle Scholar
- Schmitt TL, Espinoza CR, Loos U: Transcriptional regulation of the human sodium/iodide symporter gene by Pax8 and TTF-1. Exp Clin Endocrinol Diabetes. 2001, 109: 27-31. 10.1055/s-2001-11016.View ArticlePubMedGoogle Scholar
- Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA: A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol. 2002, 16: 2266-2282. 10.1210/me.2002-0109.View ArticlePubMedGoogle Scholar
- Puppin C, Arturi F, Ferretti E, Russo D, Sacco R, Tell G, Damante G, Filetti S: Transcriptional regulation of human NIS gene: a role for Redox factor-1. Endocrinology. 2004, 145: 1290-1293. 10.1210/en.2003-1250.View ArticlePubMedGoogle Scholar
- Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G: Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 1994, 54: 4744-4749.PubMedGoogle Scholar
- Pang XP, Hershman JM, Chung M, Pekary AE: Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology. 1989, 125: 1783-1788.View ArticlePubMedGoogle Scholar
- Puppin C, Presta I, D'Elia AV, Tell G, Arturi F, Russo D, Filetti S, Damante G: Functional interaction among thyroid-specific transcription factors: Pax8 regulates the activity of Hex promoter. Mol Cell Endocrinol. 2004, 214: 117-125. 10.1016/j.mce.2003.10.061.View ArticlePubMedGoogle Scholar
- Arturi F, Lacroix L, Presta I, Scarpelli D, Caillou B, Schlumberger M, Russo D, Bidart JM, Filetti S: Regulation by human Chorionic Gonadotropin of Sodium/Iodide symporter gene expression in the JAr human choriocarcinoma cell lines. Endocrinology. 2002, 143: 2216-2220. 10.1210/en.143.6.2216.View ArticlePubMedGoogle Scholar
- Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S: Expression pattern of the pendrin and sodium/iodide symporter (NIS) gene in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol. 2001, 145: 129-135. 10.1530/eje.0.1450129.View ArticlePubMedGoogle Scholar
- Russo D, Bulotta S, Bruno R, Arturi F, Giannasio P, Derwahl M, Bidart JM, Schlumberger M, Filetti S: Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur J Endocrinol. 2001, 145: 591-597. 10.1530/eje.0.1450591.View ArticlePubMedGoogle Scholar
- Weiss SJ, Philp NJ, Grollman EF: Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology. 1984, 114: 1090-1098.View ArticlePubMedGoogle Scholar
- Latchman DS: Transcription factor mutations and human disease. N Engl J Med. 1996, 334: 28-33. 10.1056/NEJM199601043340108.View ArticlePubMedGoogle Scholar
- Damante G, Tell G, Di Lauro R: A unique combination of transcription factors controls differentiation of thyroid cells. Prog Nucleic Acid Res Mol Biol. 2001, 66: 307-356.View ArticlePubMedGoogle Scholar
- Dai G, Levy O, Carrasco N: Cloning and characterization of the thyroid iodide transporter. Nature. 1996, 379: 458-460. 10.1038/379458a0.View ArticlePubMedGoogle Scholar
- Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J: Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun. 1997, 240: 832-838. 10.1006/bbrc.1997.7715.View ArticlePubMedGoogle Scholar
- Venkataraman GM, Yatin M, Marcinek R, Ain KB: Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab. 1999, 84: 2449-2457. 10.1210/jc.84.7.2449.PubMedGoogle Scholar
- Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T: Low concentrations of the histone deacetylase inhibitor, Depsipeptide (FR901228), increase expression of the Na+/I- symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab. 2000, 86: 3430-3435. 10.1210/jc.86.7.3430.Google Scholar
- Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH: Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery. 2002, 136: 984-990. 10.1067/msy.2002.128690.View ArticleGoogle Scholar
- Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T: Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology. 2004, 145: 2865-2875. 10.1210/en.2003-1258.View ArticlePubMedGoogle Scholar
- Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G: Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2004, 89: 1006-1009. 10.1210/jc.2003-031407.View ArticlePubMedGoogle Scholar
- Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG: Retinoic acid for redifferentiation of thyroid cancer – does it hold its promise?. Eur J Endocrinol. 2003, 148: 395-402. 10.1530/eje.0.1480395.View ArticlePubMedGoogle Scholar
- Plachov D, Chowdhury K, Walther C, Simon D, Guenet JL, Gruss P: Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development. 1990, 110: 643-651.PubMedGoogle Scholar
- Zannini M, Francis-Lang H, Plachov D, Di Lauro R: Pax-8, a paired domain-containing protein, binds to a sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters. Mol Cell Biol. 1992, 12: 4230-4241.View ArticlePubMedPubMed CentralGoogle Scholar
- Pasca di Magliano M, Di Lauro R, Tannini M: PAX8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA. 2000, 97 (221): 13144-13149. 10.1073/pnas.240336397.View ArticlePubMedPubMed CentralGoogle Scholar
- Chun YS, Saji M, Geiger MA: Overexpression of TTF-1 and PAX-8 restores thyroglobulin gene promoter activity in ARO and WRO cell lines. Surgery. 1998, 124: 1100-1105. 10.1067/msy.1998.92008.View ArticlePubMedGoogle Scholar
- Damante G: Thyroid defects due to Pax8 gene mutations. Eur J Endocrinol. 1998, 139: 563-566. 10.1530/eje.0.1390563.View ArticlePubMedGoogle Scholar
- Puppin C, D'Elia AV, Pellizzari L, Russo D, Arturi F, Presta I, Filetti S, Bogue CW, Denson LA, Damante G: Thyroid-specific transcription factors control Hex promoter activity. Nucleic Acids Res. 2003, 31: 1845-1852. 10.1093/nar/gkg295.View ArticlePubMedPubMed CentralGoogle Scholar
- Guazzi S, Lonigro R, Pintonello L, Boncinelli E, Di Lauro R, Mavilio F: The thyroid transcription factor-1 gene is a candidate target for regulation by Hox proteins. EMBO J. 1994, 13: 3339-3347.PubMedPubMed CentralGoogle Scholar
- Lee WW, Lee B, Kim SJ, Jin J, Moon DH, Lee H: Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. Oncol Rep. 2003, 10: 845-849.PubMedGoogle Scholar
- Furuya F, Shimura H, Miyazaki A, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T: Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organification and retention in thyroid cancer cells. Endocrinology. 2004, 145: 5397-5405. 10.1210/en.2004-0631.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/5/80/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.